Scarica l'app Stockscreener
5.476
4.41%
-0.244
Precedente Chiudi:
$5.72
Aprire:
$5.69
Volume 24 ore:
1.32M
Relative Volume:
0.42
Capitalizzazione di mercato:
$927.66M
Reddito:
$101.21M
Utile/perdita netta:
$-569.00K
Rapporto P/E:
-273.80
EPS:
-0.02
Flusso di cassa netto:
$-56.88M
1 W Prestazione:
+1.44%
1M Prestazione:
+30.19%
6M Prestazione:
+125.01%
1 anno Prestazione:
+530.08%
Intervallo 1D:
$5.40
$5.7001
Intervallo di 1 settimana:
$5.04
$6.15
Portata 52W:
$0.40
$6.15
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Nome
Cytomx Therapeutics Inc
Settore
Industria
Telefono
650.515.3185
Indirizzo
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Confronta CTMX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
5.475 | 969.17M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.63 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-20 | Iniziato | Guggenheim | Buy |
| 2025-09-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-09-17 | Ripresa | Barclays | Overweight |
| 2025-07-31 | Iniziato | Oppenheimer | Outperform |
| 2025-05-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | Ripresa | Piper Sandler | Overweight |
| 2024-05-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-05-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-04-22 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-11-14 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-07 | Downgrade | Mizuho | Buy → Neutral |
| 2022-07-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2022-01-18 | Aggiornamento | Barclays | Underweight → Overweight |
| 2021-11-15 | Iniziato | BTIG Research | Buy |
| 2021-05-28 | Downgrade | Barclays | Equal Weight → Underweight |
| 2021-03-29 | Iniziato | JP Morgan | Overweight |
| 2021-03-23 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-09-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-06-01 | Downgrade | Jefferies | Buy → Hold |
| 2020-05-14 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-24 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-03-04 | Iniziato | Barclays | Equal Weight |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-11-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-06-13 | Iniziato | Mizuho | Buy |
| 2019-05-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-03-11 | Iniziato | Barclays | Overweight |
| 2018-11-26 | Iniziato | Piper Jaffray | Overweight |
| 2018-10-15 | Iniziato | Goldman | Neutral |
| 2018-09-13 | Iniziato | H.C. Wainwright | Buy |
| 2018-06-01 | Iniziato | SunTrust | Buy |
| 2018-01-05 | Iniziato | Citigroup | Buy |
| 2017-09-08 | Iniziato | Wedbush | Outperform |
| 2017-03-27 | Iniziato | H.C. Wainwright | Buy |
| 2017-03-02 | Iniziato | Instinet | Buy |
| 2017-01-03 | Downgrade | Oppenheimer | Outperform → Perform |
| 2015-11-02 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Cytomx Therapeutics Inc Borsa (CTMX) Ultime notizie
Is CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? - simplywall.st
Panic Selling: What hedge funds are buying CytomX Therapeutics IncJuly 2025 Institutional & Risk Managed Investment Entry Signals - baoquankhu1.vn
CytomX Therapeutics (NASDAQ:CTMX) Sets New 1-Year HighShould You Buy? - MarketBeat
Patterns Watch: Is CytomX Therapeutics Inc benefiting from interest rate changesJuly 2025 Momentum & AI Driven Stock Price Forecasts - baoquankhu1.vn
CytomX Therapeutics (NASDAQ:CTMX) Shares Down 5.3%Here's Why - MarketBeat
Guggenheim Upgrades CytomX Therapeutics (NASDAQ:CTMX) to "Strong-Buy" - MarketBeat
CytomX stock rises 31% in a month: Here's what you should know - MSN
Piper Sandler raises CytomX Therapeutics stock price target to $10 on cancer drug data - Investing.com Canada
CTMX: Barclays Raises Price Target from $6.00 to $8.00, Maintains Overweight Rating | CTMX Stock News - GuruFocus
Guggenheim Initiates Coverage of CytomX Therapeutics (CTMX) with Buy Recommendation - Nasdaq
Guggenheim Initiates Coverage on CytomX Therapeutics (CTMX) with 'Buy' Rating | CTMX Stock News - GuruFocus
CytomX Therapeutics (CTMX) Receives Target Price Upgrade from Pi - GuruFocus
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Formidable Asset Management LLC Sells 194,513 Shares of CytomX Therapeutics, Inc. $CTMX - MarketBeat
CytomX Stock Rises 31% in a Month: Here's What You Should Know - Yahoo Finance
Risk Analysis: What is LILAKs book value per shareGDP Growth & AI Powered Trade Plan Recommendations - baoquankhu1.vn
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Rockets 31% As Investors Are Less Pessimistic Than Expected - 富途资讯
CytomX Therapeutics (NASDAQ:CTMX) Reaches New 12-Month HighHere's What Happened - MarketBeat
CytomX Therapeutics' (NASDAQ:CTMX) investors will be pleased with their incredible 402% return over the last year - Yahoo Finance
CTMX Stock Price, Forecast & Analysis | CYTOMX THERAPEUTICS INC (NASDAQ:CTMX) - Chartmill
Volatility Watch: Does CytomX Therapeutics Inc have strong EBITDA margins2025 Trading Volume Trends & Weekly Watchlist of Top Performers - baoquankhu1.vn
Is CytomX Therapeutics Inc stock heavily shortedEarnings Overview Summary & Verified Short-Term Plans - baoquankhu1.vn
Drugmaker signed East Bay's biggest Q4 lease, moving away from South San Francisco - The Business Journals
Bull Run: Is CytomX Therapeutics Inc. stock a top pick in earnings seasonJobs Report & Reliable Price Breakout Alerts - Bộ Nội Vụ
Guidance Update: What hedge funds are buying CytomX Therapeutics Inc2025 AllTime Highs & Verified Technical Trade Signals - baoquankhu1.vn
Swing Trade: Will CytomX Therapeutics Inc stock recover faster than market2025 Buyback Activity & Real-Time Buy Zone Alerts - Bộ Nội Vụ
Breakout Zone: Is CytomX Therapeutics Inc. stock gaining market shareJuly 2025 Action & Weekly Setup with ROI Potential - Улправда
Gainers Report: Will CytomX Therapeutics Inc stock recover faster than marketWeekly Volume Report & Free Technical Pattern Based Buy Signals - Bộ Nội Vụ
Is CytomX Therapeutics Inc. stock dividend yield sustainableJuly 2025 Decliners & Real-Time Volume Analysis Alerts - Улправда
Is CytomX Therapeutics Inc. stock a top pick in earnings seasonJuly 2025 Summary & Weekly Top Gainers Alerts - Улправда
CytomX Therapeutics, Inc. (CTMX) Stock Analysis: A 64.45% Potential Upside Amid Innovative Biotech Ventures - DirectorsTalk Interviews
Fed Meeting: Why CytomX Therapeutics Inc. stock could outperform in 2025Portfolio Profit Report & Intraday High Probability Alerts - Улправда
Why CytomX Therapeutics Inc. stock could outperform in 2025Weekly Earnings Recap & Momentum Based Trading Signals - Улправда
Is CytomX Therapeutics Inc. stock a safe investment in uncertain marketsWeekly Trading Summary & AI Powered Market Entry Strategies - ulpravda.ru
CytomX Therapeutics announces business update and company milestones for 2026 - marketscreener.com
Cytomx Therapeutics Announces Business Update And Company Milestones For 2026 - TradingView — Track All Markets
CytomX Therapeutics (CTMX) Reveals Plans for 2026 with Promising Clinical Developments - GuruFocus
CytomX Therapeutics Announces Business Update and Company Milestones for 2026 - manilatimes.net
New colorectal and melanoma drug trials expected to yield results in 2026 - Stock Titan
Piper Sandler and HC Wainwright stay bullish on CytomX (CTMX) - MSN
Why CytomX Therapeutics Inc. stock is recommended by analystsMarket Depth Overview & Low Entry Investment Growth - Улправда
Piper Sandler and H.C. Wainwright Stay Bullish on CytomX (CTMX) - Finviz
Is CytomX Therapeutics Inc a good long term investmentVolume Analysis Techniques & Free Trading Signals to Sharpen Your Edge - Early Times
What drives CytomX Therapeutics Inc 6C1 stock priceEmerging Market Stocks & High Return Stock Picks - earlytimes.in
What analysts say about CytomX Therapeutics Inc 6C1 stockEquity Performance Review & Collaborate and Win Together - earlytimes.in
CytomX Therapeutics (NASDAQ:CTMX) Hits New 1-Year HighHere's Why - MarketBeat
What drives CytomX Therapeutics Inc stock priceWeekly Market Snapshot & Investor Community Interactions - earlytimes.in
Chart Watch: Is CytomX Therapeutics Inc stock a safe investment in uncertain markets2025 Bull vs Bear & Verified Short-Term Trading Plans - moha.gov.vn
Will CytomX Therapeutics Inc. stock recover faster than peersChart Pattern Recognition & Exceptional Return Stocks - bollywoodhelpline.com
237,081 Shares in CytomX Therapeutics, Inc. $CTMX Acquired by Precision Wealth Strategies LLC - MarketBeat
Inspire Investing LLC Acquires Shares of 522,482 CytomX Therapeutics, Inc. $CTMX - MarketBeat
Cytomx Therapeutics Inc Azioni (CTMX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.38%
1.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):